Could a common heart drug boost cancer treatment? a trial puts propranolol to the test

NCT ID NCT07727993

Not yet recruiting Disease control Sponsor: Ting Liu Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial is investigating whether adding the beta-blocker propranolol to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable locally advanced gastric or gastroesophageal junction cancer. About 49 participants will receive the combination treatment, followed by surgery. The main goal is to see if this approach leads to a complete disappearance of cancer cells in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of the beta-blocker propranolol, chemotherapy (oxaliplatin and S-1, known as SOX), and the immunotherapy toripalimab
What this could lead to: If successful, this approach could offer a new neoadjuvant treatment option for locally advanced gastric cancer, potentially increasing the chance of a complete pathological response before surgery.
What could go wrong: This is an early-phase, single-arm trial with only 49 participants, so results may not be generalizable. Adding propranolol to chemotherapy and immunotherapy could increase side effects, including low blood pressure and heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PROPRANOLOL SOX CHEMOTHERAPY TORIPALIMAB

More trials for these conditions

Other studies related to the condition(s) this trial covers.